Last reviewed · How we verify
Nicotinic Acid Methylamide — Competitive Intelligence Brief
unknown
Neuroscience
Live · refreshed every 30 min
Target snapshot
Nicotinic Acid Methylamide (nicotinyl methylamide). Nicotinic Acid Methylamide is thought to work by interacting with nicotinic acetylcholine receptors in the body.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Nicotinic Acid Methylamide TARGET | nicotinyl methylamide | unknown |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Nicotinic Acid Methylamide CI watch — RSS
- Nicotinic Acid Methylamide CI watch — Atom
- Nicotinic Acid Methylamide CI watch — JSON
- Nicotinic Acid Methylamide alone — RSS
Cite this brief
Drug Landscape (2026). Nicotinic Acid Methylamide — Competitive Intelligence Brief. https://druglandscape.com/ci/nicotinyl-methylamide. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing